Porphyrin Formation in Actinic Keratosis and Basal Cell Carcinoma after Topical Application of Methyl 5-Aminolevulinate  by Angell-Petersen, Even et al.
Porphyrin Formation in Actinic Keratosis and Basal
Cell Carcinoma after Topical Application of Methyl
5-Aminolevulinate
Even Angell-Petersen1, Roar Sørensen2, Trond Warloe1, Ana Maria Soler1, Johan Moan2, Qian Peng3
and Karl-Erik Giercksky1
Photodynamic therapy using topical methyl 5-aminolevulinate (MAL) is a new treatment modality for basal cell
carcinoma (BCC) and actinic keratosis (AK). MAL induces endogenous porphyrins, which act as photo-
sensitizers. Pharmacokinetic studies of the porphyrin-inducing effect of MAL creams (Metvixs) applied in
different concentrations (16–160 mg/g) and application times are presented. Surface fluorescence measurements
were used to monitor porphyrin accumulation in 18 superficial BCCs and 32 AKs. For both lesion types, the
fluorescence increased during the first 13 of 28 hours of continuous MAL application. A 20-fold site-to-site
variation was observed, and there were no significant MAL concentration dependencies. The selectivity
between lesions and normal skin was 10-fold during the first hours and decreased throughout the application
time. Fluorescence microscopy images of tissue sections from 32 nodular BCCs were analyzed to calculate the
porphyrin content in tumor tissue as a function of depth. Significant correlation to MAL concentration was seen
within the tumors treated for 3 hours. Increase to 18-hour MAL application enhanced the fluorescence levels in
superficial tumor layers, but not in deep layers. In conclusion, application of the 160 mg/g cream for 3 hours
gave advantageous porphyrin distributions for all types of lesions.
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INTRODUCTION
Photodynamic therapy (PDT) is a local treatment involving
the administration of a tumor-localizing photosensitizing
substance (Dougherty et al., 1998). Light absorption by the
photosensitizer generates reactive oxygen species, which are
cytotoxic to cells. Following pioneering preclinical work
(Malik and Lugaci, 1987; Peng et al., 1987), topical PDT
using precursors of endogenous photosensitizing porphyrins
was introduced by Kennedy et al. (1990). Since then, a
variety of skin disorders have been treated using the precursor
aminolevulinic acid (ALA) as well as other more lipophilic
ALA derivatives (Peng et al., 1997; Morton et al., 2002). ALA
is a naturally occurring compound metabolized intracellu-
larly in the heme synthesis pathway. Excess of endogenous
ALA, or several ALA derivatives, leads to accumulation of the
photosensitizer protoporphyrin IX, the immediate precursor
of heme.
The transport of ALA through tissues and into cells has
been reported to be suboptimal (Wolf et al., 1993; Martin
et al., 1995; Peng et al., 1995). More lipophilic ALA esters
were introduced to overcome this limitation and to improve
the bioavailability (Kloek and Beijersbergen, 1996; Peng
et al., 1996). Differences between ALA and its esters have
been shown for a variety of key issues, including uptake and
protoporphyrin IX production in cells (Gaullier et al., 1997;
Rud et al., 2000), transport through tissues (Bigelow et al.,
2001; de Rosa et al., 2003; van den Akker et al., 2003),
ability to induce protoporphyrin IX production in tissues
(Fritsch et al., 1998; Lange et al., 1999; Perotti et al., 2002),
effect of vehicles (Casas et al., 2001; Lopez et al., 2004),
systemic uptake (Moan et al., 2001), and pain felt during PDT
(Wiegell et al., 2003). Successful treatment of actinic
keratosis (AK) (Szeimies et al., 2002; Freeman et al., 2003;
Pariser et al., 2003) and basal cell carcinoma (BCC) (Soler
et al., 2001; Horn et al., 2003; Rhodes et al., 2004) has been
achieved using methyl 5-aminolevulinate (MAL), the methyl
ester of ALA. Topical PDT using an MAL cream (Metvixs,
Photocure, Norway) and red light is currently an approved
treatment modality for AK (Europe, Australia, USA) and
certain types of BCC (Europe, Australia), and has during the
last 7 years been used to treat more than 30,000 lesions at our
institution. The cream has an MAL concentration of 160 mg/g
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and is applied for 3 hours before the lesion is exposed to red
light.
The limiting factor in PDT with topical drug application is
transport of the drug into the tumor and the resulting
photosensitizer distribution, rather than attenuation of the
light (Svaasand et al., 1996). By non-invasive in vivo
measurements of fluorescence, it is possible to monitor the
build-up of the photosensitizer (Pottier et al., 1986) for the
purpose of developing drug applications that yield high
photosensitizer concentration in the tumor and sufficient
selectivity versus normal tissues. In the present study, this
technique has been used to monitor the porphyrin fluore-
scence in AK, superficial BCC, and normal skin during
28 hours application of oil-in-water creams with MAL
concentrations 16, 80, or 160 mg/g. A highly selective
build-up of porphyrin fluorescence is demonstrated for both
AK and BCC. The data show how the intensity and selectivity
of porphyrin fluorescence depend on the cream application
time. Additionally, a new, extended analysis of fluorescence
microscopy images from a previously published study (Peng
et al., 2001) of porphyrin fluorescence in thick nodular BCCs
is presented. The new analysis made it possible to calculate
the depth profiles of the porphyrin fluorescence achieved by
different MAL cream concentrations and application times.
RESULTS
In vivo monitoring of surface porphyrin fluorescence from AK
and superficial BCC
Significant porphyrin fluorescence was observed from the
surface of BCC, AK, and normal skin during MAL cream
application (see Figure S1). The recorded spectra revealed
fluorescence spectral characteristics typical for protoporphyr-
in IX, with peaks around 635 and 705 nm (see Figure S2). The
time integral (area under curve (AUC)) of porphyrin
fluorescence was larger than the measurement system’s
detection limit for 20 of the 24 AK lesions, 16 of the 18
BCC lesions, and 22 of the 41 normal skin sites. There was a
large site-to-site variability with 20-fold variation within BCC
and AK lesions, and 5-fold variation within normal skin sites.
The mean AUCs for the different lesion types and cream
concentrations are shown in Figure 1. Analysis of variance
revealed no statistically significant effect of MAL concentra-
tion on porphyrin fluorescence for BCC, AK, or normal skin
adjacent to BCC. These findings should be interpreted
cautiously, as the number of samples was insufficient to
detect dependencies smaller than the large site-to-site
variability. For normal skin adjacent to AK, there was less
porphyrin fluorescence from sites treated with the lowest
cream concentration than from sites treated with the two
higher concentrations (P¼ 0.001). The same difference was
seen if all normal skin sites in both patient groups were
combined (P¼ 0.004). No effect of patient age or site location
was observed.
Most of the fluorescence increase appeared during the first
13 hours of MAL cream application, and the fluorescence
seemed to reach a plateau after 21 hours. As seen in Figure 2,
a similar fluorescence development was seen for AK and
BCC, and the exponential rise to max model – with time
coefficients t of 7.6 and 6.1 hours, respectively – fit the data.
For the normal skin sites, the plateau was less obvious, and
the exponential model did not fit significantly better than a
simple linear model. The placebo-treated sites showed a
small, but statistically significant decrease throughout the
cream application time (Figure 2). This effect seemed
identical for normal skin sites and AK lesions and was most
likely due to minor changes in the optical properties of tissues
caused by the presence of the cream. For both AKs and BCCs,
this change was taken into account before calculating the
lesion to normal skin selectivity ratios of porphyrin fluore-
scence. There were no significant differences between the
selectivity ratios for the different MAL concentrations (data
not shown), in spite of the above-mentioned difference in
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Figure 1. Detected porphyrin fluorescence for different site types treated
with different cream concentrations. For each MAL concentration, the bars
show means7SEM of time integrals (AUC) from AK patients (n¼8) or
superficial BCC patients (n¼ 6). For each cream-treated site, the time integral
from the adjacent untreated site was subtracted to correct for background
contribution and estimate porphyrin fluorescence exclusively.
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Figure 2. Accumulation of surface porphyrin fluorescence during MAL
application. The porphyrin fluorescence from lesions (J) and adjacent
normal skin (&) is plotted as a function of cream application time for AK
patients and superficial BCC patients. For each time point, the mean7SD was
calculated for all the sites regardless of MAL cream concentration. The total
number of MAL-treated lesions and normal skin sites (taking into account
exclusions) were, respectively, 23 and 24 for the AK patients and 18 and 17
for the BCC patients. Data from eight placebo-treated AK and normal skin
sites are shown in gray. The regression lines were calculated using the
exponential rise to max model Fð1  et=tÞ.
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porphyrin fluorescence for normal skin. Selectivity ratios
calculated for all concentrations combined are shown in
Figure 3. For the first measurement points at 1 and 3 hours,
the signal from normal skin adjacent to BCC was so low
compared to the measurement uncertainty that the selectivity
ratio could not be estimated directly. However, by using
the regression lines (Figure 2) as interpolations, 10 to 1
selectivity ratios were estimated for both AK and BCC at these
time points. The selectivity then decayed throughout the
28-hour cream application and finally reached 3:1 for AK and
5:1 for BCC.
Quantification of porphyrin fluorescence in tissue sections
of thick BCCs
The analysis of fluorescence microscopy images from thick
BCCs showed that porphyrin fluorescence depended on both
cream application time and MAL concentration. Depth
profiles of the fluorescence were calculated for all samples,
and the average profile for each treatment mode is shown in
Figure 4. It was apparent from the hematoxylin & eosin
images that the upper 50 mm of each sample consisted mainly
of epidermal tissue covering the tumors. According to two-
way analysis of variance, the average porphyrin fluorescence
in this region was significantly higher after 18 hours of MAL
cream application than after 3 hours (P¼ 0.005), but there
was no difference between the different cream concentra-
tions. This time dependency is also apparent from the depth
profiles in Figure 4, where distinct similar peaks in the
0–50 mm epidermal region are seen only for the 18-hour
treatment modes. The hematoxylin & eosin images showed
that below 100mm into the samples, the fluorescence was
exclusively from tumor tissue. According to two-way analysis
of variance tests, comparing the average values of the
profiles, this tumor fluorescence did not increase significantly
with the cream application time. It did, however, increase
with the MAL cream concentration (P¼ 0.017), but exclu-
sively for tumors treated for 3 hours. In the 18-hour samples,
there was no tendency to a concentration dependency.
Surprisingly, the shapes of the profiles in Figure 4 also suggest
that in terms of relative intensity, the 18-hour application
induces a more superficial porphyrin distribution than the
3-hour application.
DISCUSSION
The present data show that topical MAL application induces a
buildup of fluorescence around 635 nm in both BCC and AK.
The spectral characteristics indicate that this fluorescence
was mainly from the photosensitizing protoporphyrin IX, as
expected from studies identifying the porphyrins formed in
cells and tissues exposed to ALA esters (Gaullier et al., 1997;
Fritsch et al., 1998; Tunstall et al., 2002). According to the
surface fluorescence measurements, the photosensitizer
content in AKs and superficial BCCs increased throughout
the first 13 hours of MAL application (Figure 2). This is in
agreement with results from other studies where the
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Figure 3. Lesion to normal skin selectivity ratio of porphyrin fluorescence
as a function of cream application time. The ratios were calculated for
AK patients and superficial BCC patients, for all cream concentrations
combined. The ratios at each time point were calculated as ðMALlesion 
PlacebolesionÞ=ðMALnormalskin  PlacebonormalskinÞ from the means shown in
Figure 2, using the placebo data from AK patients for both the AK and the BCC
patients. For each time point, the error bars show the relative SEM of the
selectivity ratio, calculated from the SEMs of the lesion and normal skin
measurements. For BCC, the ratio values at 1 and 3 hours are omitted due to
the fact that no significant difference between placebo- and MAL-treated
normal skin were detected at these time points. The (—) show the ratio
between the regression lines from Figure 2.
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Figure 4. Depth profiles of porphyrin fluorescence in biopsies from thick
nodular BCCs. Each curve shows the mean7SEM of profiles from sites treated
with MAL cream concentrations 160 mg /g, 80 mg /g, or 16 mg /g for (a)
3 hours or (b) 18 hours. There were six samples for each 160 mg /g treatment
mode and five samples for each other treatment mode. The maximum depths
of tumor tissue in the samples were in the range 1.0–2.3 mm, and, for each
treatment mode, the average profile is plotted down to the depth where
fluorescence data were available from three or more tumors.
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fluorescence increased throughout a 6-hour application on
AKs (Fritsch et al., 1998) and a 4-hour application on BCC
(Thompson et al., 2001), and suggests that PDT with long
MAL application times might be beneficial. However, in a
multicenter dose-ranging study with treatment of BCCs using
application times in the range 1–18 hours, no differences
were seen in response rates within groups that had at least
3 hours application. The average response rate for superficial
BCC was 95% (Basset Seguin N et al. (2000). J Eur Acad
Dermatol Venereol 14(S1):39 (abstr)). This suggests that the
photosensitizer content achieved after 3 hours is sufficient for
PDT. For AKs, a tendency that 1-hour application is less
efficient than 3 hours has been reported (Braathen L et al.
(2000). J Eur Acad Dermatol Venereol 14(S1): 38 (abstr.), but
longer treatment times have, to our knowledge, not been
tested. Taking into account the high response to MAL PDT
with 3 hours of cream application (Szeimies et al., 2002;
Freeman et al., 2003; Pariser et al., 2003), it is unlikely that
treatment with longer application times, utilizing the higher
porphyrin content which may be achieved according to our
results (Figure 1), would improve the treatment considerably.
Furthermore, it was evident, particularly in the AK patients,
that longer application times lead to a less beneficial ratio
between the porphyrin content in lesion and normal tissue
(Figure 3), and from this one might expect more discomfort
and side effects. In our institution, the general experience
with overnight MAL application compared to 3-hour applica-
tion is that it leads to more pain during the light exposure,
particularly for patients with severely photo-aged skin.
The new analysis of the images from thick nodular BCCs
revealed an MAL concentration dependency not previously
detected. The original analysis only measured the fluores-
cence intensity along a narrow sample rectangle through the
tumor, and the main end point was the depth of the porphyrin
fluorescence and not its intensity. The new analysis provided
intensity profiles based on the fluorescence from all tumor
tissue in each section, thus reducing a source of error and
increasing the strength of statistical comparison between the
different treatment modes. The profiles can also be used to
estimate the depth of porphyrin fluorescence. Such an
analysis resulted in identical results as those previously
published (within 75%, results not shown), with 90–100%
penetration into the tumors treated with the 160 mg/g cream
for 3 hours (Peng et al., 2001). The shape of the profiles in
Figure 4 indicates that at 3 hours, although porphyrin
fluorescence was detected up to 1.8–2.1 mm into the lesions,
the fluorescence intensity decreased after 1.0–1.2 mm. This
decrease seems less distinct for the tumors treated for
18 hours, but it should be noticed that (by coincidence) no
data from tumor tissue below 1.2–1.6 mm was available from
those samples. In our clinical experience, increasing the
application time from 3 to 18 hours does not improve the
response rate for thick BCCs. Also, all studies reporting
successful PDT of such lesions have been carried out with
short application times and have involved a debulking
procedure to enhance the drug penetration into the deeper
layers of the tumors (Soler et al., 1999, 2001; Horn et al.,
2003; Rhodes et al., 2004).
Both the decreasing surface fluorescence ratios for AKs
and superficial BCCs (Figure 3) and the great fluorescence in
the upper 50mm of the thick BCC samples at 18 hours
(Figure 4) indicate that short MAL application times produce
the highest lesion to normal skin ratios of photosensitizer
content. Ten-fold selectivity of surface fluorescence was seen
through the first hours of cream application, and this is in
agreement with the ratio reported in a study using a
comparable detection method through 6 hours of MAL
application on superficial BCC (Thompson et al., 2001).
Another study using chemical extraction of porphyrins in
biopsies from AK patients showed 10-fold selectivity after
6 hours (Fritsch et al., 1998). In both of these studies,
significantly less selectivity was found after application of
creams containing ALA instead of MAL. Other studies with
ALA have indicated a 2–5-fold selectivity after 2–6 hours of
cream application (Golub et al., 1999; af Klinteberg et al.,
1999). It has been reported that for both ALA and MAL,
hardly any porphyrin is produced in the dermis (Kennedy
et al., 1990; Peng et al., 2001). Thus, the low porphyrin
content in normal skin is to a large degree due to a
combination of the thinness of the epidermis and good
selectivity towards epithelial tissues (Martin et al., 1995).
Such a distribution of photosensitizer is likely to be of clinical
significance, keeping the PDT-induced damage to normal
skin superficial.
In vivo surface fluorescence measurements are affected by
the optical properties of tissues (Sinaasappel and Sterenborg,
1993). This is a likely cause for some of the observed site-
to-site variations in porphyrin fluorescence (illustrated by the
large error bars in Figure 2). Moreover, it is a source of error
when comparing measurements from tissues with different
optical properties. Thus, the values given in Figure 3 are just
ratios in porphyrin fluorescence and not ratios in porphyrin
concentration. The reported 5–10-fold increase of blood
content in AK and BCC compared to normal skin (Newell
et al., 2003) reduces the fluorescence, due to strong
absorption of the blue excitation light by hemoglobin,
suggesting that the ratios shown in Figure 3 may under-
estimate the actual selectivity in porphyrin content.
In conclusion, topical application of MAL cream induced
selective accumulation of the photosensitizer protoporphyrin
IX, or possibly other porphyrins with similar fluorescence
spectra, in both AKs and BCCs. The 160 mg/g cream lead to
the highest porphyrin content in thick BCCs after 3 hours
application. Increasing the application time did not seem to
benefit the porphyrin content, except in layers close to the
surface. The surface porphyrin fluorescence from both AKs
and superficial BCCs increased for the first 13–20 hours of
cream application, whereas the lesion to normal skin
selectivity ratio decreased. Creams with 16–160 mg/g MAL
induced similar porphyrin levels, and the dose dependency
within this concentration range is small compared to the
lesion-to-lesion variability. Our studies support the current
160 mg/g–3-hour treatment regimen for MAL PDT. The results
show that longer application times reduce the selectivity and
that lower concentrations reduce the porphyrin content in
thick lesions. They also suggest that longer application times
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mainly increase the porphyrin content in superficial lesions
and not in thick lesions.
MATERIALS AND METHODS
The study was prospective, randomized, and double-blinded. The
trial was conducted in accordance with the Declaration of Helsinki
Principles and was reviewed and approved by The Norwegian
Medicines Control Authority, the Regional Ethics Committee, and
the institutional review board.
Patients and lesions
A total of eight patients (seven men and one woman, mean age 79
years) with 32 lesions of AK (four lesions per patient) located on the
trunk (18 lesions), extremities (five), scalp (six), and the temple
(three); and six patients (three men and three women, mean age 73
years) with 18 lesions of superficial BCC (three lesions per patient)
located on the trunk (10 lesions), extremities (seven), and temple
(one) were included in the study. Informed consent was obtained
from all patients. All BCC lesions were verified by cytology (Berner
et al., 1999) and were characterized as superficial by clinical
diagnosis. The AK lesions were included based on clinical diagnosis
and were of class II on a I–III scoring with I, II, and III representing
thin, medium, and hypertrophic AK, respectively.
Drug formulation and randomization
The three BCC lesions per patient were randomized to treatment
with three different oil-in-water cream formulations containing 16,
80, and 160 mg /g MAL (Metvixs, Photocure ASA, Oslo, Norway).
The four AK lesions per patient were randomized to the same
formulations as well as a placebo cream.
Non-invasive in vivo fluorescence detection
MAL-induced porphyrin fluorescence was detected by surface
measurements using a fiber optic probe connected to a lumine-
scence spectrometer (LS5, Perkin Elmer, Wellesley, MA) (Moan
et al., 1995). The probe gave about 20 mW cm2 of 407 nm
excitation light to a 1 6 mm2 sample area and collected
fluorescence light at a numerical aperture of about 0.3. The emission
wavelength was fixed at 635 nm to monitor protoporphyrin IX
fluorescence, but from selected sites the whole fluorescence
spectrum from 550 to 750 nm was recorded.
Treatment procedure
Any crusts covering the AK or superficial BCC lesions were removed
using a small surgical curette without causing any bleeding.
Subsequently, an approximately 1 mm thick layer of MAL cream
covered by a transparent occlusive dressing (OpSite Flexifix, Smith &
Nephew, Hull, UK) was applied to the lesion as well as to a normal
skin site 3–5 cm from each lesion. In addition, an untreated site with
normal skin next to each lesion was covered by occlusive dressing
exclusively. Duplicate fluorescence measurements with perpendi-
cular sample areas were made on lesions and adjacent occluded sites
immediately after cream application and after 1, 3, 5, 7, 9, 11, 13,
21, 23, 25, and 28 hours. All measurements were made through the
occlusive dressing with the probe gently pressed towards the surface
to push the cream aside from the sample area. One measurement
series from a normal skin site treated with 16 mg /g cream was
excluded as an outlier due to a 10-fold larger than usual difference
between the duplicate measurements and a 7-fold larger than usual
fluorescence intensity. One measurement series from an AK lesion
treated with 160 mg /g cream was excluded due to bleeding.
Data analysis
The duplicate measurement values from each site at each time point
were averaged. The measurement values from untreated normal skin
sites were used as estimates of the background signal, which
consisted of autofluorescence, reflected light and detector dark
current. At each time point, the MAL induced porphyrin fluores-
cence for each cream-treated normal skin and lesion site was
estimated by subtracting the value from the adjacent untreated
normal skin site. Time integrals, or AUC, of porphyrin fluorescence
were calculated for all treated sites. The AUC values were used to
compare the different sites and cream concentrations statistically
using the non-parametric analysis of variance (Kruskal–Wallis) and
rank sum (Mann–Whitney) tests. Also, AUCs from individual sites
were compared to the detection limit of the measurement system,
defined as three times the standard deviation in AUCs from placebo-
treated sites. Time series of average porphyrin fluorescence within a
site type were calculated and fitted to an ‘‘exponential rise to max’’
model by nonlinear regression using the Marquardt–Levenberg
algorithm (SigmaStat, Systat Software Inc., CA). Ratios of lesion to
normal skin selectivity were calculated for all time points. Standard
errors of the mean (SEMs) for the selectivity ratios were calculated as
the root sum square of the relative SEMs of lesion and normal skin
measurements.
Analysis of images from thick basal cell carcinoma tissue
sections
In a previously published clinical trial (Peng et al., 2001), porphyrin
distribution in biopsies from 32 thick BCCs treated for 3 or 18 hours
with MAL creams were studied by CCD-based fluorescence
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Figure 5. Method for calculating the porphyrin fluorescence depth profile in
a nodular BCC sample. The white light and fluorescence microscopy images
are from a lesion treated with 160 mg /g MAL cream for 18 hours. (a) The
dotted line in the porphyrin fluorescence image shows the tumor and
epithelial tissue demarcation, as determined from (b) the white light images of
the same section and (c) an adjacent hematoxylin & eosin-stained section.
(a) The dashed line is the surface position that is used in the (d) calculation of
the depth profile. The depth profile is the average fluorescence intensity
within the demarcation as a function of distance to the surface. Bar¼500 mm.
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microscopy. An extended investigation of the images from this trial
was now performed using a tailor made image analysis method.
Three microscopy images were available from each tumor: a
porphyrin fluorescence image, a white light image of the same
tissue section, and a hematoxylin & eosin-stained image of an
adjacent section. The fluorescence images were corrected for
nonuniform illumination and for the background autofluorescence
determined from samples receiving no MAL treatment. The white
light and hematoxylin & eosin images were used, as shown in
Figure 5, to mask out non-tumor connective tissue areas and to
calculate porphyrin fluorescence depth profiles for epidermal and
tumor tissue exclusively.
CONFLICT OF INTEREST
Medical use of methyl 5-aminolavulinate is patented by Trond Warloe, Johan
Moan, Qian Peng, and Karl-Erik Giercksky (among others). The patent is
currently owned by Photocure ASA, in which Trond Warloe is a minor
shareholder.
ACKNOWLEDGMENTS
This work has been supported in part by PhotoCure ASA (Oslo, Norway). We
thank Anneli B. Madsen and Vladimir Iani for their assistance.
SUPPLEMENTARY MATERIAL
Figure S1. Measurement series of surface fluorescence from sample lesions
and adjacent normal skin.
Figure S2. Fluorescence spectra from an actinic keratosis lesion.
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